IDNA — IDNA Genomics Public Income Statement
0.000.00%
Last trade - 00:00- €81.15m
- €83.58m
- €0.48m
Annual income statement for IDNA Genomics Public, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 7 W | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.78 | 1.08 | 0.493 | 0.478 |
| Cost of Revenue | ||||
| Gross Profit | 0.715 | 0.894 | 0.323 | 0.13 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.491 | 1.34 | 1.7 | 3.3 |
| Operating Profit | 0.29 | -0.266 | -1.2 | -2.82 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.25 | -0.365 | -1.34 | -2.97 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 0.25 | -0.361 | -1.34 | -2.97 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 0.25 | -0.361 | -1.34 | -2.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 0.25 | -0.361 | -1.34 | -2.52 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.096 | -0.139 | -0.487 | -0.599 |
| Dividends per Share |